Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease

Brain

Volumn 139, Issue 9, 2016, Pages 2528-2539

  Chételat, Gaël ^a,b,c,d   Ossenkoppele, Rik ^e,f,g   Villemagne, Victor L ^h   Perrotin, Audrey ^a,b,c,d   Landeau, Brigitte ^a,b,c,d   Mézenge, Florence ^a,b,c,d   Jagust, William J ⁱ   Dore, Vincent ^h,j   Miller, Bruce L ^g   Egret, Stéphanie ^a,b,c,d   Seeley, William W ^g   Van Der Flier, Wiesje M ^f   La Joie, Renaud ^a,b,c,d   Ames, David ^k,l   Van Berckel, Bart N M ^f   Scheltens, Philip ^e   Barkhof, Frederik ^f   Rowe, Christopher C ^h   Masters, Colin L ^m   De La Sayette, Vincent ^a,b,c,d   Bouwman, Femke ^e   Rabinovici, Gil D ^g,i,n   more..

^a Centre Cyceron   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h AUSTIN HEALTH   (Australia)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CSIRO   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^m FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

ⁿ LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

more..

Author keywords

Alzheimer's disease; amyloid; MRI; PET; retrosplenial posterior cingulate

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN SCINTISCANNING; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RETROSPLENIAL CORTEX; SOMATOFORM DISORDER; AMNESIA; ATROPHY; CINGULATE GYRUS; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; HIPPOCAMPUS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

AGED; ALZHEIMER DISEASE; AMNESIA; ATROPHY; FEMALE; FOLLOW-UP STUDIES; GYRUS CINGULI; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 84994810302     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww159     Document Type: Article

References (55)

1. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636-45.
2. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of alzheimer disease at national institute on aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-73.
3. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-44.
4. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009; 66: 1557-62.
5. Chételat G, Desgranges B, Landeau B, Mézenge F, Poline JB, de la Sayette V, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008; 131: 60-71.
6. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128: 755-66.
7. Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Förstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging 2004; 25: 1051-6.
8. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-b assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79: 1636-44.
9. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
10. Duits FH, Teunissen CE, Bouwman FH, Visser P-J, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid Alzheimer profile?: easily said, but what does it mean?. Alzheimers Dement 2014; 10: 713-723.e2.
11. Fouquet M, Besson FL, Gonneaud J, La Joie R, Chételat G. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan. Neuropsychol Rev 2014; 24: 290-9.
12. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-14.
13. Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol 2013; 125: 581-93.
14. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
15. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221-9.
16. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-Analysis. JAMA 2015; 313: 1924-38.
17. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement 2013; 9: e106-9.
18. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
19. La Joie R, Perrotin A, Barré L, Hommet C, Mézenge F, Ibazizene M, et al. Region-specific hierarchy between atrophy, hypometabolism, and b-Amyloid (Ab) load in Alzheimer's disease dementia. J Neurosci 2012; 32: 16265-73.
20. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70: 327-40.
21. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Någren K, et al. Assessment of beta-Amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-9.
22. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, et al. Amyloid-b 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 2015; 85: 692-700.
23. Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010; 119: 1-4.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
26. Mendez MF, Lee AS, Joshi A, Shapira JS. Nonamnestic presentations of early-onset Alzheimer's disease. Am J Alzheimers Dis Other Demen 2012; 27: 413-20.
27. Mevel K, Landeau B, Fouquet M, La Joie R, Villain N, Mézenge F, et al. Age effect on the default mode network, inner thoughts, and cognitive abilities. Neurobiol Aging 2013; 34: 1292-301.
28. Monsell SE, Kukull WA, Roher AE, Maarouf CL, Serrano G, Beach TG, et al. Characterizing apolipoprotein E "4 carriers and noncarriers with the clinical diagnosis of mild to moderate alzheimer dementia and minimal b-Amyloid peptide plaques. JAMA Neurol 2015; 72: 1124-31.
29. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampalmediated beta-Amyloid deposition in elderly subjects. Brain 2009; 132: 1310-23.
30. Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 2015; 77: 942-52.
31. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry 2003; 74: 1521-9.
32. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-Analysis. JAMA 2015a; 313: 1939-49.
33. Ossenkoppele R, Pijnenburg YAL, Perry DC, Cohn-Sheehy BI, Scheltens NME, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 2015b; 138: 2732-49.
34. Ossenkoppele R, Prins ND, Pijnenburg YAL, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013; 9: 414-21.
35. Ossenkoppele R, Zwan MD, Tolboom N, van Assema DME, Adriaanse SF, Kloet RW, et al. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. Brain 2012; 135: 2115-25.
36. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid b-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-9.
37. Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64: 388-401.
38. Rabinovici GD, Seeley WW, Kim EJ, Gorno-Tempini ML, Rascovsky K, Pagliaro TA, et al. Distinct MRI atrophy patterns in autopsyproven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2007; 22: 474-88.
39. Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci 2012; 13: 713-26.
40. Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, Lah JJ, et al. Deficient high-Affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2010; 119: 221-33.
41. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-83.
42. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-To-moderate Alzheimer's disease. N Engl J Med 2014; 370: 322-33.
43. Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 2014; 82: 230-8.
44. Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Lå ngström B, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-36.
45. Serrano-Pozo A, Qian J, Monsell SE, Blacker D, Gó mez-Isla T, Betensky RA, et al. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol 2014; 75: 597-601.
46. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
47. Shimada H, Ataka S, Takeuchi J, Mori H, Wada Y, Watanabe Y, et al. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-Alzheimer disease-Type dementia as having AD. J Geriatr Psychiatry Neurol 2011; 24: 123-6.
48. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex J Devoted Study Nerv Syst Behav 2007; 43: 835-45.
49. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 2014; 84: 608-22.
50. Takeuchi J, Shimada H, Ataka S, Kawabe J, Mori H, Mizuno K, et al. Clinical features of Pittsburgh compound-B-negative dementia. Dement Geriatr Cogn Disord 2012; 34: 112-20.
51. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-29.
52. Vann SD, Aggleton JP, Maguire EA. What does the retrosplenial cortex do?. Nat Rev Neurosci 2009; 10: 792-802.
53. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol 2015; 14: 114-24.
54. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-92.
55. Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis 2014; 41: 801-7.